Effects of dual chelation therapy with deferasirox and deferoxamine in patients with beta thalassaemia major

Vox Sanguinis ◽  
2022 ◽  
Author(s):  
Ahmad Zargari ◽  
Simon Wu ◽  
Anthea Greenway ◽  
Ken Cheng ◽  
Zane Kaplan
2007 ◽  
Vol 78 (1) ◽  
pp. 48-51 ◽  
Author(s):  
Efthimia Vlachaki ◽  
Elissavet Ioannidou-Papagiannaki ◽  
Konstantinos Tziomalos ◽  
Styliani Haralambidou-Vranitsa ◽  
Vassilios Perifanis ◽  
...  

2007 ◽  
Vol 122 (11) ◽  
pp. 1253-1256 ◽  
Author(s):  
D Thio ◽  
V Prasad ◽  
P Anslow ◽  
P Lennox

AbstractObjective:The aim of this report was to highlight the fact that hearing loss in thalassaemia patients can be related to marrow expansion affecting the ossicles, resulting in a conductive loss.Case report:A six-year-old boy with transfusion-dependent beta-thalassaemia developed a unilateral hearing loss shortly after commencing desferrioxamine therapy. Otoxicity was assumed, but the deficit was later found to be of a conductive nature, due to marrow proliferation within the ossicular chain as a consequence of the disease process – a phenomenon previously unreported in the literature.Conclusion:It is important to elucidate the precise nature of new onset hearing loss in patients receiving iron chelation therapy, in order to avoid unnecessary cessation of much needed medication, on the assumption of ototoxicity.


1982 ◽  
Vol 57 (12) ◽  
pp. 929-933 ◽  
Author(s):  
S Fargion ◽  
M T Taddei ◽  
V Gabutti ◽  
A Piga ◽  
A Di Palma ◽  
...  

2020 ◽  
Vol 40 (7) ◽  
pp. 902-911 ◽  
Author(s):  
Malihe Nourollahpour Shiadeh ◽  
Elena Cassinerio ◽  
Maryam Modarres ◽  
Armin Zareiyan ◽  
Zeinab Hamzehgardeshi ◽  
...  

Author(s):  
P Papadantonakis ◽  
O Neofotistou ◽  
A Vasiliadi ◽  
A Skoutelis ◽  
A Tsatsakis ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document